Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15210421 | 0.89 | LMNA (0.59) | LMNATDP1MEN1KMT2AMAPT | |
| SCHEMBL2543365 | 0.86 | LMNA (0.47) | LMNATDP1MEN1KMT2AMAPT | |
| SCHEMBL2539831 | 0.86 | LMNA (0.63) | LMNATDP1MEN1KMT2AMAPT | |
| SCHEMBL5483462 | 0.84 | LMNA (0.48) | LMNATDP1MEN1KMT2AMAPT | |
| SCHEMBL2544801 | 0.81 | LMNA (0.45) | LMNATDP1MEN1KMT2AMAPT | |
| SCHEMBL2537170 | 0.81 | LMNA (0.45) | LMNATDP1MEN1KMT2AMAPT | |
| SCHEMBL7375735 | 0.79 | LMNA (0.57) | LMNATDP1MEN1KMT2AMAPT | |
| SCHEMBL3425538 | 0.74 | LMNA (0.72) | LMNATDP1MEN1KMT2AMAPT | |
| SCHEMBL17412398 | 0.74 | MEN1 (0.55) | LMNATDP1MEN1KMT2AMAPT | |
| SCHEMBL15210654 | 0.74 | LMNA (0.60) | LMNATDP1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044055-B2 | 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| EP-2079711-B1 | 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20090291962-A1 | 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-11-26 | — | — | US | disclosed |
| EP-2079711-A2 | 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008050301-A2 | 2- PHENYL- 6-AMINOCARBONYL- PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291962-A1 | 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR | P2RY12, P2RY13, P2RY2 | LMNA 2912/4885TDP1 1962/4885MEN1 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.